Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation. (October 2018) - Hurvitz, Sara A.; Quek, Ruben G.W.; Ettl, Johannes; Rugo, Hope; Bhattacharyya, Helen; Hannah, Alison L.; Litton, Jennifer Keating